SCHEDULE: Valion Bio: Major Shareholder Sells Significant Stake

An amendment to a Schedule 13D filing reveals substantial stock sales by 3i, LP and Tumim Stone Capital, LLC, significantly reducing their beneficial ownership in Valion Bio, Inc.

Summary

• This filing is an amendment (Amendment No. 2) to a Schedule 13D concerning Valion Bio, Inc. (the Issuer).
• The reporting persons are 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow.
• As of August 14, 2026, the reporting persons' beneficial ownership is based on 15,776,805 shares of Common Stock outstanding.
• 3i, LP directly holds 75,069 shares and has the potential to acquire an additional 1,667,630 shares through warrants, a convertible note, and preferred stock conversions, subject to a 9.99% beneficial ownership limitation (Blocker).
• 3i Management LLC and Maier J. Tarlow indirectly hold the same potential shares as 3i, LP.
• Tumim Stone Capital, LLC holds 0.00% beneficial ownership.
• Significant transactions occurred on August 12 and 13, 2026, including large sales of common stock by 3i, LP and Tumim Stone, and acquisitions upon conversion of Series B and Series C Preferred Stock by 3i, LP.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant share sales by reporting persons and a substantial decrease in their beneficial ownership percentage, indicating a potential loss of confidence or strategic shift.

Negatives

• 3i, LP sold 11,676,430 shares of Common Stock on August 12, 2026, at a price of $0.3969 per share.
• Tumim Stone Capital, LLC sold 49,242 shares of Common Stock on August 12, 2026, at a price of $1.1060 per share.
• The beneficial ownership percentage for 3i, LP, 3i Management LLC, and Maier J. Tarlow decreased to 9.9% from a previous undisclosed percentage.
• The beneficial ownership for Tumim Stone Capital, LLC is 0.0%.

Risks

• The 'Blocker' provision limits the exercise of warrants and conversions of convertible notes and preferred stock to a 9.99% beneficial ownership threshold, potentially restricting future share acquisition.
• The significant sales by reporting persons could indicate a reduced conviction in the company's future prospects or a strategic divestment.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the 'Blocker' provision on future share acquisitions suggests potential limitations on the reporting persons' ability to increase their stake.

Industry Context

StockSavvy.ai notes that significant share sales by major holders, especially in a company like Valion Bio which appears to be in a growth or development phase given the preferred stock and convertible note structures, can often signal a shift in investor sentiment or strategy, potentially impacting market perception.

Related Party Transactions

• The reporting persons (3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow) are acting in concert regarding the securities of Valion Bio, Inc.

Stakeholder Impact

• Shareholders may be concerned by the significant stock sales, potentially leading to downward pressure on the stock price.
• Creditors and noteholders might view the sales as a sign of reduced confidence from a significant investor, potentially impacting perceptions of the company's financial stability.

Next Steps

• The reporting persons may continue to engage in transactions with the Issuer's securities, subject to the beneficial ownership limitations.
• Further amendments to the Schedule 13D will be filed if there are material changes in beneficial ownership or other relevant information.

Key Dates

Recommendation

The significant reduction in beneficial ownership by key investors suggests a potential lack of conviction or a strategic shift, which warrants caution. However, the remaining stake and potential for future conversions, albeit limited, suggest that a complete sell-off is not yet indicated. Therefore, a 'hold' position allows for further observation of the company's performance and the investors' future actions.

Keywords

Schedule 13D, Valion Bio, 3i, LP, Tumim Stone Capital, Beneficial Ownership, Stock Sale, Convertible Preferred Stock, Warrants